Accord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
Accord Healthcare is voluntarily recalling specific lots of Levothyroxine Sodium tablets because they may contain less active ingredient than labeled.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II for a subpotent drug, which fits the rubric criterion for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Accord Healthcare, Inc. is voluntarily recalling specific lots of Levothyroxine Sodium Tablets, USP, 175 mcg. The recall was initiated on August 6, 2026, and is currently ongoing. The affected product is packaged in 90-count and 1,000-count bottles and is distributed nationwide within the United States.
The reason for the recall is that the tablets are subpotent, meaning they may contain less of the active ingredient than stated on the label. The affected lots include D2402642, D2401832, D2402525, D2402527, D2402526, D2402644, and D2402643. These lots have expiration dates of either August 31, 2026, or November 30, 2026.
Patients taking this medication should check their bottles for the specific lot numbers and expiration dates listed above. If the medication matches the recalled lots, patients should stop using it and contact their healthcare provider or pharmacist for guidance on alternative treatment options. The recall was classified as Class II by the FDA, indicating a reasonable probability that the use of the product could cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- ACCORD HEALTHCARE, INC.
- Category
- Drug — Thyroid Hormone
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- a) Lot #: D2402642
- Exp. Date 11/30/2026 b) Lot #: D2401832
- Exp. Date 08/31/2026
- D2402525
- D2402527
- D2402526
- D2402644
- D2402643
- Exp. Date 11/30/2026.
UPCs (12)
- 0316729447157
- 0316729449151
- 0316729452151
- 0316729454155
- 0316729453158
- 0316729448154
- 0316729451154
- 0316729457156
- 0316729450157
- 0316729456159
- 0316729458153
- 0316729455152
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same manufacturer · ACCORD HEALTHCARE, INC.
See all →- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · subpotent drug
See all →- LowImprimisRx Recalls Subpotent Povidone Iodine and Proparacaine Ophthalmic Solution
FDA (Drugs) · 2026-09-16
Similar recalls
- SevereAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- HighLevothyroxine Sodium Tablets Recalled Due to Subpotency Nationwide
FDA (Drugs) · 2024-12-11
- HighLevothyroxine Sodium Tablets 88 mcg Recall for Subpotency
FDA (Drugs) · 2025-05-07
- ModerateLevothyroxine Sodium Tablets Nationwide Recall Due to Subpotency
FDA (Drugs) · 2025-05-07